Preclinical Imaging Evaluation of Novel TSPO-PET Ligand 2-(5,7-Diethyl-2-(4-(2-[18F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([18F]VUIIS1008) in Glioma

被引：0
|
作者：
Dewei Tang
Michael L. Nickels
M. Noor Tantawy
Jason R. Buck
H. Charles Manning
机构：
[1] Vanderbilt University Medical Center,Vanderbilt University Institute of Imaging Science (VUIIS)
[2] Vanderbilt University Medical Center,Department of Radiology and Radiological Sciences
[3] Vanderbilt University Medical Center,Program in Chemical and Physical Biology
[4] Vanderbilt University Medical Center,Vanderbilt
[5] Vanderbilt University,Ingram Cancer Center
[6] Vanderbilt University Medical Center,Department of Biomedical Engineering
[7] Vanderbilt University Medical Center,Department of Neurosurgery
来源：
Molecular Imaging and Biology | 2014年 / 16卷
关键词：
PET; DPA-714; VUIIS1008; TSPO; Glioma; Cancer imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：813 / 820
页数：7
相关论文
共 26 条
  • [1] Preclinical Imaging Evaluation of Novel TSPO-PET Ligand 2-(5,7-Diethyl-2-(4-(2-[18F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([18F]VUIIS1008) in Glioma
    Tang, Dewei
    Nickels, Michael L.
    Tantawy, M. Noor
    Buck, Jason R.
    Manning, H. Charles
    MOLECULAR IMAGING AND BIOLOGY, 2014, 16 (06) : 813 - 820
  • [2] Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma
    Tang, Dewei
    Li, Jun
    Nickels, Michael L.
    Huang, Gang
    Cohen, Allison S.
    Manning, H. Charles
    MOLECULAR IMAGING AND BIOLOGY, 2019, 21 (01) : 113 - 121
  • [3] Preclinical Evaluation of a Novel TSPO PET Ligand 2-(7-Butyl-2-(4-(2-[18F]Fluoroethoxy)phenyl)-5-Methylpyrazolo[1,5-a]Pyrimidin-3-yl)-N,N-Diethylacetamide (18F-VUIIS1018A) to Image Glioma
    Dewei Tang
    Jun Li
    Michael L. Nickels
    Gang Huang
    Allison S. Cohen
    H. Charles Manning
    Molecular Imaging and Biology, 2019, 21 : 113 - 121
  • [4] Evaluation of the novel TSPO radiotracer 2-(7-butyl-2-(4-(2-([18F]fluoroethoxy)phenyl)-5-methylpyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide in a preclinical model of neuroinflammation
    Tang, Dewei
    Fujinaga, Masayuki
    Hatori, Akiko
    Zhang, Yiding
    Yamasaki, Tomoteru
    Xie, Lin
    Mod, Wakana
    Kumata, Katsushi
    Liu, Jianjun
    Manning, H. Charles
    Huang, Gang
    Zhang, Ming-Rong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 1 - 8
  • [5] Quantitative Preclinical Imaging of TSPO Expression in Glioma Using N,N-Diethyl-2-(2(4-(2-18F-Fluoroethoxy)Phenyl)-5,7-Dimethylpyrazolo[1,5-a]Pyrimidin-3-yl)Acetamide
    Tang, Dewei
    Hight, Matthew R.
    McKinley, Eliot T.
    Fu, Allie
    Buck, Jason R.
    Smith, R. Adam
    Tantawy, Mohammed Noor
    Peterson, Todd E.
    Colvin, Daniel C.
    Ansari, M. Sib
    Nickels, Michael
    Manning, H. Charles
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (02) : 287 - 294
  • [6] The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer
    Zeglis, Brian M.
    Pillarsetty, NagaVaraKishore
    Divilov, Vadim
    Blasberg, Ronald A.
    Lewis, Jason S.
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (05) : 683 - 696
  • [7] Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide):: a promising radioligand for quantification of pancreatic β-cell mass with positron emission tomography (PET)
    Wängler, B
    Schneider, S
    Thews, O
    Schirrmacher, E
    Comagic, S
    Feilen, P
    Schwanstecher, C
    Schwanstecher, M
    Shiue, CY
    Alavi, A
    Höhnemann, S
    Piel, M
    Rösch, F
    Schirrmacher, R
    NUCLEAR MEDICINE AND BIOLOGY, 2004, 31 (05) : 639 - 647
  • [8] Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3
    P. Mahy
    M. De Bast
    P. H. Leveque
    J. Gillart
    D. Labar
    J. Marchand
    V. Gregoire
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 1263 - 1272
  • [9] Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3
    Mahy, P
    De Bast, M
    Leveque, PH
    Gillart, J
    Labar, D
    Marchand, J
    Gregoire, V
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (09) : 1263 - 1272
  • [10] Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F] fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate
    Zhou, Zhengyuan
    McDougald, Darryl
    Meshaw, Rebecca
    Balyasnikova, Irina
    Zalutsky, Michael R.
    Vaidyanathan, Ganesan
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 100 : 24 - 35
123